Conclusion
HER2-negative, TNBC
The universal gBRCA testing and adjuvant olaparib are highly cost-effective in TNBC and potentially cost-effective in all HER2-negative BC. Hence the universal testing strategy is recommended for adoption by current guidelines for gBRCA testing. Moreover, owing to the nature of mathematical modelling, the results should be interpreted cautiously.